Equirus on Cadila
Downgrade to SHORT, TP Rs 224
Expect earnings pressure even beyond FY22E amid
Limited high-value launches in pipeline
High concentration risk in existing biz
Longer gestation for monetization of vaccines
Assign lower P/E on higher concentration led by Asacol HD